Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abvc Biopharma (ABVC) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Abvc Biopharma (ABVC) over the last 13 years, with Q3 2025 value amounting to 156.2%.

  • Abvc Biopharma's EBITDA Margin fell 610600.0% to 156.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 1165.75%, marking a year-over-year decrease of 2614900.0%. This contributed to the annual value of 976.0% for FY2024, which is 41337500.0% up from last year.
  • As of Q3 2025, Abvc Biopharma's EBITDA Margin stood at 156.2%, which was down 610600.0% from 1713.42% recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's EBITDA Margin peaked at 2127.68% during Q4 2021, and registered a low of 239206.22% during Q1 2024.
  • Its 5-year average for EBITDA Margin is 20707.02%, with a median of 1399.05% in 2023.
  • In the last 5 years, Abvc Biopharma's EBITDA Margin plummeted by 2000000000bps in 2024 and then surged by 2000000000bps in 2025.
  • Quarter analysis of 5 years shows Abvc Biopharma's EBITDA Margin stood at 2127.68% in 2021, then tumbled by -136bps to 757.2% in 2022, then tumbled by -2255bps to 17832.06% in 2023, then tumbled by -114bps to 38139.47% in 2024, then soared by 100bps to 156.2% in 2025.
  • Its last three reported values are 156.2% in Q3 2025, 1713.42% for Q2 2025, and 359.03% during Q1 2025.